Clinical Trials in China / NCT07791576
Recruiting
Phase 2
Population PK-guided ATG Dosing in Haplo-HSCT
NCT07791576 · tracked via the Priya Life Science China tracker
Condition(s) studied
Hematopoietic Stem Cell Transplantation
Investigational drug(s) / intervention(s)
Anti Thymocyte Globulin: Population pharmacokinetic formula-guided targeted ATG dosing plus classical GVHD prophylaxis regimen
Study summary
To evaluate the safety and efficacy of a population pharmacokinetics (PK)-guided targeted ATG dosing strategy in haploidentical stem cell transplantation and to observe the GVHD-free, relapse-free survival (GRFS) in the cohort receiving this strategy.
Eligibility
Inclusion Criteria:
1. Patients with indications for allogeneic hematopoietic stem cell transplantation, with malignant hematologic diseases in CR1 or CR2 before transplantation.
2. Have an HLA-matched sibling, unrelated, or haploidentical donor.
3. Age ≥ 14 years and ≤ 65 years.
4. Liver function: ALT and AST ≤ 2.5 × upper limit of normal, bilirubin ≤ 2 × upper limit of normal.
5. Renal function: creatinine ≤ upper limit of normal.
6. No uncontrolled infection or severe mental or psychological disorders.
7. ECOG performance status score of 0-2.
8. Signed informed consent.
Exclusion Criteria:
1. No HLA-matched donor.
2. Malignant hematologic disease in CR3 or higher disease stage, or refractory/relapsed status，or second transplantation.
3. Patient age \< 14 years or \> 65 years.
4. Pregnancy of either the donor or the recipient.
5. Presence of mental illness or other conditions that preclude compliance with the protocol.
Primary outcome measure(s)
- 1-year GVHD-free and relapse-free survival rate(1-year-GRFS) — 1 year after treatment
GRFS is defined as the time from randomization to the first occurrence of grade III-IV acute GVHD, chronic GVHD requiring systemic immunosuppressive therapy, or death due to disease relapse, whichever occurs first. The cumulative incidence of GRFS will be estimated using the Fine-Gray competing risk model.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Chinese PLA General Hospital | Beijing | Beijing Municipality | Recruiting |
More Chinese PLA General Hospital trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07791576 on ClinicalTrials.gov ↗ ← All trials in China